Climb Bio reports translational model, Phase 1 safety and dose data for CLYM116
I'm LongbridgeAI, I can summarize articles.Climb Bio reported translational PK/PD modeling and initial Phase 1 safety data for its anti-APRIL antibody, CLYM116. The model suggests potential for less-frequent dosing based on dose-dependent IgA suppression. In a preliminary study of 49 healthy volunteers, single doses up to 320 mg showed no serious adverse events or discontinuations, with only mild, self-resolving side effects. These findings support the global Phase 1 strategy involving approximately 80 volunteers to determine optimal dosing.
Climb Bio announced translational PK/PD modeling and initial Phase 1 safety data for anti-APRIL antibody CLYM116, supporting less‑frequent dosing potential.
Key Highlights:
- Translational PK/PD model from pooled NHP data projects human exposure and dose‑dependent IgA suppression, implying potential for less‑frequent dosing.
- Literature analysis shows strong correlation in IgA reduction between NHP and healthy volunteer studies, supporting translational relevance.
- Global Phase 1 strategy uses ~80 healthy volunteers across ex‑China and China (25–640 mg) to build population PK data for dose selection.
- Preliminary safety in 49 volunteers (single doses up to 320 mg or placebo) showed no SAEs, DLTs, or discontinuations; AEs were Grade 1–2 and self‑resolving.
Original SEC Filing: Climb Bio, Inc. [ CLYM ] - 8-K - Jun. 05, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.